Thromboembolism Clinical Trial
Official title:
The Risk for VTE Among Patients in the Medical Wards - Prospective Observational Study.
Patients hospitalized in internal wards are at risk for VTE. The current guidelines recommend
the use of thromboprophylaxis for 7-10 days among patients who are at increased risk for VTE.
Yet several retrospective studies have shown that the compliance with this guideline is low.
Physicians are often reluctant to administer LMWH to their fragile patients mainly because
they are not convince that the risk associated with such therapy is greater than the risk for
VTE.
In the current study, data concerning the use of thromboprophylaxis among patients admitted
to the medical wards will be collected. The occurrence of bleeding or thrombotic event will
be evaluated prospectively.
Data concerning the use of LMWH among patients admitted to the medical wards at the Hadassah
University Hospital will be collected prospectively from the electronic medical records. The
occurrence of bleeding episodes or thrombotic events will be followed for the next 90 days
following discharge from the hospital.
The percent of patients actually treated by LMWH among patients entitled for such therapy
according to the most updated international guidelines will be evaluated. The risk of minor
and major bleeding will be compared among those given thromboprophylaxis and those who were
not treated. Similar comparison will be made for thrombotic events.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05794165 -
Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism
|
Phase 2 | |
Active, not recruiting |
NCT05563883 -
Atrial Fibrillation and Cancer: a Nationwide French Cohort Study
|
||
Terminated |
NCT02475187 -
Observational Study of Thrombogenic Properties in 220 Patients With Proximal Femur Fracture
|
||
Recruiting |
NCT00982514 -
Thromboembolic Complications Related to Asparaginase in Children With Acute Lymphoblastic Leukemia (ALL) Treated According to NOPHO ALL 2008
|
N/A | |
Completed |
NCT01420809 -
Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection
|
N/A | |
Terminated |
NCT00206089 -
Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events
|
Phase 3 | |
Completed |
NCT00014352 -
Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer
|
Phase 2 | |
Completed |
NCT00000614 -
Prevention of Recurrent Venous Thromboembolism (PREVENT)
|
Phase 3 | |
Active, not recruiting |
NCT05656963 -
The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
|
||
Completed |
NCT04719182 -
Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19
|
||
Completed |
NCT02935751 -
Apixaban Discontinuation Prior to Major Surgery
|
||
Terminated |
NCT02579122 -
REVIparin-BRIDging-in a General Practice Setting in GErmany
|
||
Completed |
NCT01696760 -
Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology
|
N/A | |
Completed |
NCT00986154 -
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
|
Phase 3 | |
Terminated |
NCT00662688 -
Chemotherapy With or Without Dalteparin in Treating Patients With Metastatic Pancreatic Cancer
|
Phase 3 | |
Completed |
NCT00260988 -
A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery
|
Phase 2/Phase 3 | |
Terminated |
NCT00031837 -
Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
|
Phase 3 | |
Completed |
NCT03877770 -
DVT After Cardiac Procedure
|
||
Completed |
NCT00024297 -
Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters
|
N/A | |
Recruiting |
NCT06118957 -
Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery
|
Phase 2 |